Playback speed
10 seconds
ESMO 2019 Updated IMpower110 Trial Results: With Consistent OS/PFS Improvement, Atezolizumab Is a New 1st-Line Treatment Option for PD-L1-High Stage IV NSCLC
By
Yale Cancer Center
FEATURING
Roy Herbst
By
Yale Cancer Center
FEATURING
Roy Herbst
1,734 views
January 7, 2020
Login to view comments.
Click here to Login